Combination therapy of rituximab and corticosteroids for patients with refractory chronic immune thrombocytopenic purpura: report of two cases

@inproceedings{Ling2013CombinationTO,
  title={Combination therapy of rituximab and corticosteroids for patients with refractory chronic immune thrombocytopenic purpura: report of two cases},
  author={Yun Ling and Xinyu Qian and Xiangshan Cao},
  booktitle={Contemporary oncology},
  year={2013}
}
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder, for which rituximab has been proven to be an effective treatment. The response rate was reported to be approximately 60% in refractory ITP patients. However, the response time is slower than expected, and the mechanism of action of rituximab in ITP is still unclear. Thus, sometimes, the use of a combination therapy with rituximab according to different patient conditions is necessary. We report two refractory chronic ITP cases… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-9 of 9 references

Immune thrombocytopenic purpura--the changing therapeutic landscape.

The New England journal of medicine • 2006
View 1 Excerpt